Updates are available Correction dated 2025-03-15

Article History

Received: 21 March 2024

Accepted: 20 January 2025

First Online: 20 February 2025

Change Date: 10 March 2025

Change Type: Update

Change Details: The original online version of this article was revised: In this article, Figs. 1 and 2 were wrongly numbered inadvertently during the production process; Fig. 1 should have been Fig. 2 and vice versa.

Change Date: 15 March 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s10549-025-07677-8

Declarations

:

: Prof. Dr. Achim Wöckel received consulting fees from Amgen, AstraZeneca, Celgene, Eli Lilly and Company, Novartis, Pfizer, Roche, MSD, Genomic Health, Organon, Seagen, Exact Sciences, Gilead, Daiichi Sankyo, and Stemline, honoraria from AstraZeneca, Aurikamed, Celgene, Eli Lilly and Company, Novartis, Pfizer, Roche, MSD, Genomic Health, Seagen, Exact Sciences, Gilead, Daiichi Sankyo, Onkowissen, and Stemline, and support for attending meetings and travel from AstraZeneca, Eli Lilly and Company, Novartis, Pfizer, Roche, MSD, Seagen, Gilead, and Daiichi Sankyo. Prof. Dr. Tjoung-Won Park-Simon received honoraria and payment for expert testimony from Roche, Astra Zeneca, GSK, Pfizer, Daiichi Sankyo, Eli Lilly and Company, MSD, NCO, Eisai, Seagen, Exact Sciences, Novartis, Pfizer, Gilead, and Onkowissen, support for attending meetings and travel from Roche, Astra Zeneca, GSK, Pfizer, Eli Lilly and Company, Gilead, Novartis, and holds a leadership or fiduciary role at AGO Mamma Komisssion. Prof. Dr. Hans Tesch received consulting fees, honoraria, payment for expert testimony, and support for attending meetings and travel from Pfizer, Novartis, Eli Lilly and Company, Roche, MSD, GSK, Seagen, and Daiichi Sankyo. Agnieszka Korfel and Kirsten Raab are employees and minor shareholders of Eli Lilly and Company.

: All patients were informed about the voluntary, confidential, and anonymous nature of this study. Additionally, patients were given relevant information in accordance with the European Pharmaceutical Marketing Research Association (ESOMAR)/European Pharmaceutical Market Research Association (EPhMRA) code of conduct such as data privacy. All respondents provided written consent.

: All patients were informed about the voluntary, confidential, and anonymous nature of this study. Additionally, patients were given relevant information in accordance with the European Pharmaceutical Marketing Research Association (ESOMAR)/European Pharmaceutical Market Research Association (EPhMRA) code of conduct such as data privacy. All respondents provided written consent.